A Transcriptional Fingerprint of Estrogen in Human Breast Cancer Predicts Patient Survival  by Yu, Jianjun et al.
RESEARCH ARTICLE
A Transcriptional Fingerprint of
Estrogen in Human Breast Cancer
Predicts Patient Survival1,2
Jianjun Yu*,†,3, Jindan Yu†,3, Kevin E. Cordero‡,
Michael D. Johnson#, Debashis Ghosh§,
James M. Rae‡,¶, Arul M. Chinnaiyan†,∥,¶,4
and Marc E. Lippman‡,4
*Bioinformatics Program, The University of Michigan
Medical Center, Ann Arbor, MI 48109 USA; Departments
of †Pathology, ‡Internal Medicine, §Biostatistics, ∥Urology,
The University of Michigan Medical Center, Ann Arbor,
MI 48109 USA; ¶The Comprehensive Cancer Center,
The University of Michigan Medical Center, Ann Arbor,
MI 48109 USA; #Department of Oncology, Georgetown
University, Washington, DC 20007 USA
Abstract
Estrogen signaling plays an essential role in breast cancer progression, and estrogen receptor (ER) status has long
been a marker of hormone responsiveness. However, ER status alone has been an incomplete predictor of endo-
crine therapy, as some ER+ tumors, nevertheless, have poor prognosis. Here we sought to use expression pro-
filing of ER+ breast cancer cells to screen for a robust estrogen-regulated gene signature that may serve as a
better indicator of cancer outcome. We identified 532 estrogen-induced genes and further developed a 73-gene
signature that best separated a training set of 286 primary breast carcinomas into prognostic subtypes by stepwise
cross-validation. Notably, this signature predicts clinical outcome in over 10 patient cohorts as well as their respec-
tive ER+ subcohorts. Further, this signature separates patients who have received endocrine therapy into two
prognostic subgroups, suggesting its specificity as a measure of estrogen signaling, and thus hormone sensitivity.
The 73-gene signature also provides additional predictive value for patient survival, independent of other clinical
parameters, and outperforms other previously reported molecular outcome signatures. Taken together, these data
demonstrate the power of using cell culture systems to screen for robust gene signatures of clinical relevance.
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Introduction
Breast cancer is the most common type of cancer among women in
the industrialized world, accounting for nearly one of every three
cancers diagnosed. Estrogen is essential for the normal growth and
differentiation of the mammary gland, and plays a critical role in
the pathogenesis and progression of breast cancer [1]. Increased
lifetime exposure to estrogen is a well-known factor for increased
breast cancer risk [1], and drugs that block the effects of estrogen
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has been used to inhibit the growth of hormone-dependent breast
cancers [2]. In the last few decades, systemic adjuvant therapy to
patients with predicted poor prognosis has significantly increased
breast cancer survival [3]. Current prognostic markers for breast
cancer include tumor stage, size, histologic grade, and estrogen recep-
tor (ER) status. However, approximately one of four patients diag-
nosed with breast cancer nevertheless die from the disease [4],
indicating the insufficiency of current prognostic biomarkers. In ad-
dition, a large number of patients with ER-positive tumors failed on
endocrine therapy, suggesting the need of more precise biomarkers of
therapy prediction.
Taking advantage of global expression profiling, molecular pre-
dictors have been developed to classify and predict patient prognosis
[5–10]. This prognostication of breast cancer outcome may be used
for the selection of high-risk patient for adjuvant therapy. Transcrip-
tional changes of these predictor genes are presumed to reflect the
activity of essential signaling pathways in tumors and thus greatly in-
crease the prediction power. For example, the expression of prostate-
specific antigen indicates the activation of androgen receptor and
serves as a much better diagnostic/prognostic biomarker of prostate
cancer than androgen receptor itself. Similarly, for several decades,
ER status has been used as a marker of hormone responsiveness to
guide adjuvant therapy, with ER+ tumors having significantly better
clinical outcome [11]. Some ER+ tumors, nevertheless, incur disease
recurrence, indicating that ER status alone is an incomplete assessor
and that additional biomarkers are required. A transcriptional finger-
print of estrogen may better reflect the activity of estrogen signaling,
thus being a more definitive predictor of breast cancer recurrence and
patients’ response to hormonal therapy.
In this study, we attempted to delineate downstream effector genes
of estrogen signaling. We hypothesized that these genes may indicate
an activated state of ER, and thus predict cancer outcome and hor-
mone responsiveness. By expression profiling of ER+ breast cancer cells
treated with 17β-estradiol, we identified a set of estrogen-induced
genes. Of these, we developed a 73-gene signature, which predicts pa-
tient survival in over 10 independent breast cancer cohorts. More im-
portantly, our signature is associated with clinical outcome in patients
who have received endocrine therapy. This signature also demonstrated
superior performance over previously reported molecular signatures.
Materials and Methods
Cell Culture
Breast cancer cell lines (MCF-7, T47-D, and BT-474) were main-
tained as previously described [12]. For defined estrogen culture experi-
ments, cells were rinsed in PBS, grown in steroid-depleted media (phenol
red–free improved minimal essential media) supplemented with 10%
charcoal-stripped calf bovine serum for 2 days, and treated with 10−9 M
17β-estradiol for 1, 2, 4, 8, 12, or 24 hours as described previously [13].
RNA Extraction and Microarray Experiments
RNA was isolated, labeled, and hybridized according to the Affy-
metrix protocol (Affymetrix GeneChip Expression Analysis Technical
Manual, Rev. 3) by the University of Michigan Comprehensive
Cancer Center Affymetrix and cDNA Microarray Core Facility as de-
scribed previously [13]. All primary array data have been deposited in
the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.
gov/geo/) with series number GSE3834.
Affymetrix Microarray Data Analysis
Data from microarray experiments were calculated, normalized
and log2-transformed using RMAExpress [14]. As described previ-
ously [13], the MCF-7 profiles were generated on the Affymetrix
U133A platform, and the other profiles were generated on the Affy-
metrix U133 Plus 2.0 platform; we thus only considered 22,283
probe sets that were common in both platforms for subsequent analy-
sis. Expression values within each cell line were first z-transformed to
zero mean and unit variance. Time-course experiments were ana-
lyzed using Extraction of Differential Gene Expression (EDGE) [15]
to identify genes differentially expressed in estrogen-treated relative to
estrogen-starved cells. Multiple hypothesis testing was adjusted by
false discovery rate (FDR). A total of 1314 probe sets were identi-
fied differentially expressed over time with FDR less than 0.01. These
genes were then subjected to hierarchical clustering, which resulted
in one estrogen-induced gene cluster containing 532 probe sets and
the other estrogen-inhibited gene cluster containing 782 probe sets.
For subsequent analyses, only genes in the estrogen-induced cluster
were used as we are more interested in estrogen-activated events during
tumor progression.
Analysis of Primary Breast Tumor Data Using the
Estrogen-Regulated Gene Set
All primary breast tumor sets used in this study were collected by
ONCOMINE [16] from previous publications or from the National
Center for Biotechnology Information GEO database. Genes within
each data set were normalized to zero mean and unit variance. The
largest Affymetrix U133A breast cancer data set [10], containing
286 primary breast carcinomas, was used as the training set to con-
duct cross-validation and to develop an optimal gene set as previously
described [17]. All other data sets were used as independent test
sets for validation purpose. The basic cross-validation procedure is
as follows: 1) Fit Cox regression model and calculate the Cox score
for each gene in the training set of Wang et al. 2) Choose a set
J of possible values of Cox scores S from step 1), and let Pmin =
1, emin = 1. 3) For each S in J, do the following: 4) perform K-
means clustering (K = 2) using only genes with absolute Cox scores
greater than S. 5) Perform a log-rank test to test whether the two
clusters have different survival rates. Name the P-value of this test
as P. 6) If P > Pmin, then return to step 3). 7) Perform 10-fold
cross-validation by the nearest centroid classification based on
the class memberships defined by the clusters obtained in step 4).
Name the misclassification error as e. 8) If e ≤ emin, then let Sopt =
S, Pmin = P, and emin = e, and return to step 3). Otherwise, return to
step 3) without changing the value of Sopt. The optimal value of S is
the value of Sopt when the cycle of this procedure terminates, and
the optimal gene signature is designated as genes with absolute
Cox scores greater than Sopt. The two clusters from K-means clus-
tering based on these optimal genes are designated accordingly as
either high-risk or low-risk by Kaplan-Meier (KM) survival analysis.
Individual samples in the test data sets are then predicted as high-risk
or low-risk by the nearest centroid classification. When both the
training and the test data sets used the same Affymetrix platform,
probe set IDs were used to cross-refer the two data sets. Otherwise,
gene symbols were used to map genes from the training set to the
test sets. When multiple report identifiers were found for one gene
on a given platform, expressions of such reporter IDs were averaged
per gene.
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Figure 1. (a) Heat map representation of 532 in vitro estrogen-regulated genes across three ER+, estrogen-sensitive breast cancer cell
lines (MCF-7, T47-D, and BT-474) after 17β-estradiol treatment. Each row represents a gene, and each column represents a sample
treated with estrogen for different time periods (0, 1, 2, 4, 8, 12, or 24 hours with replicates). Red indicates high expression; blue,
low expression. (b–d) Molecular concept map (MCM) analysis of the 532 estrogen-regulated genes (yellow node with black frame) show-
ing enrichment networks of (b) previously reported estrogen-regulated molecular concepts both in vitro and in vivo, (c) gene ontology
concepts, and (d) breast cancer progression and prognosis concepts. Each node represents a molecular concept or a set of biologically
related genes. The node size is proportional to the number of genes in the concept. Each edge represents a statistically significant
enrichment (see Table W1 for P values). Concepts of upregulated genes by estrogen treatment are indicated by light green nodes. Blue,
holly green, and purple nodes represent genes upregulated in ER+ breast cancer, high-grade breast cancer, and breast cancer patients
with poor outcome, respectively. Enriched gene ontology terms are represented by orange nodes.
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Survival Analysis
Kaplan-Meier survival plots were compared by log-rank test in R
(the R Foundation, http://www.r-project.org) for individual data sets.
The end point of interest for survival analysis is recurrence-free sur-
vival unless the data set only provides overall survival (OS) informa-
tion. Multivariate Cox proportional-hazards regression analysis was
conducted on the van de Vijver et al. data set in R. Concordance
of sample prediction memberships by different signatures was tested
in SPSS 11.5 for Windows (SPSS Inc., Chicago, IL).
Results
Identification of Estrogen-Regulated Genes
To identify robust estrogen-regulated genes, we employed three
ER+, estrogen-responsive breast cancer cell lines, i.e., MCF-7,
T47-D, and BT-474. We stimulated these cells with 17β-estradiol
to emulate the transcriptional events induced by estrogen signaling
in vivo. To ensure that we capture the transcriptional changes due
to direct regulation by estrogen, rather than downstream effects,
we focused primarily on early time-points (0, 1, 2, 4, 8, 12, and
24 hours) after estrogen stimulation [15]. By a time-course analysis
on expression profiling of these cell lines, we identified 532 estrogen-
induced probe sets, representing 446 unique genes (FDR < 0.01, see
the Materials and Methods section and Figure 1a).
Several lines of evidence support that the genes we selected represent
a true downstream transcriptional network of estrogen signaling. Firstly,
a subset of these genes, including PGR, PDZK1, CTSD, MYC, MYB,
MYBL1, MYBL2, STK6, Ki-67, and GREB1, have been previously
confirmed to be induced by estrogen [13,18,19]. Secondly, molecular
concept map (MCM) analysis [20], which allows for the identification
of molecular correlates of our gene set, revealed significant enrichment
of upregulated by estrogen treatment signatures (P ≤ .001, odds ratios ≥
4.35) previously identified by several independent groups [21–23] (Fig-
ure 1b and Table W1). To evaluate the biologic relevance of our gene
set in vivo, MCM analysis of cancer profiling concepts found strong
enrichment of over-expressed in ER+ breast cancer concepts derived from
a number of human breast cancer profiling studies executed by indepen-
dent investigators [5,8,10,24]. Therefore, our estrogen-regulated gene
set is relevant to previously identified gene sets of estrogen regulation
Figure 2. Estrogen-regulated genes stratified breast cancer samples into two groups with significantly different prognoses. (a) Rep-
resentation of stepwise cross-validation on the training set of Wang et al. Left panel, the number of misclassified samples by cross-
validation. Right panel, survival difference of the resulted two clusters when a particular set of genes were used. x axis, the number of
top genes, ordered by their corresponding survival significance. Dashed line, threshold used to select the optimal gene signature. (b)
K-mean clustering representation of the 73 estrogen-regulated genes in the training cohort (left) and its Kaplan-Meier survival plot (right).
The 73 genes were selected based on minimal misclassification error by 10-fold cross validation in the space of the initial identified
532 genes.
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reported from both in vitro cell line experiments and in vivo tumor pro-
filing. Interestingly, integrative analysis with a public genome-wide lo-
cation data of ER occupancy [25] showed that a highly significant
portion (P < .00001) of our estrogen-induced genes are direct targets
of ER, suggesting that our gene set may represent the direct transcrip-
tional network evoked by activated ER.
To obtain an overall annotation of our estrogen-regulated genes,
we performedMCM analysis on gene ontology concepts. Significantly
enriched gene ontology categories include DNA replication, regulation
of cell cycle, protein folding, tRNA processing, cytokinesis, DNA replica-
tion, and DNA repair (Figure 1c). This result is consistent with previ-
ously reported functions of estrogen-regulated genes [13,26].
Estrogen-Regulated Gene Signature Predicts Breast
Cancer Outcome
Intriguingly, another distinct interaction network revealed by
MCM analysis enriched in the over-expressed in high grade breast
cancer signatures from various data sets such as the data sets of Miller
et al. [5], Sotiriou et al. [24], and van de Veer et al. [9] (Figure 1d ).
Notably, this enrichment network also includes several concepts of
over-expressed in metastasis, dead, or recurrent breast cancers, suggesting
a link between our gene signature and breast cancer outcome. Thus,
we next attempted to confirm this survival association using breast
cancer expression profiling data sets. We performed K-mean cluster-
ing (K = 2) with Pearson correlation distance of 286 node-negative
primary breast carcinomas [10] (Figure W1 a). Kaplan-Meier survival
analysis revealed that the resulting two clusters differed significantly
in patient outcome (P = .002; Figure W1 a). The high-risk group
with poorer outcome has higher expression of several known ER tar-
gets [13,19], such asMYBL1,MYBL2,MKI67, andMCM2. By con-
trast, good-outcome genes that are over-expressed in the low-risk group
include PGR, CD44, ADD1, and PTGER3.
To develop an optimal outcome predictor using top survival-related
genes, we ranked the 532 estrogen-regulated genes by their correspond-
ing survival significance and performed stepwise cross-validation. Our
results demonstrated a set of top-ranked 73 genes (Table W2) that
yielded optimal survival association with the least cross-validation
error (Figure 2a). This 73-gene signature successfully dichotomized
Figure 3. The 73-gene outcome signature predicts clinical outcome of breast cancer. The 73-gene signature was applied to predict indi-
vidual test samples as either ‘‘low-risk’’ or ‘‘high-risk’’ for the studies of (a) van 't Veer et al., (b) Pawitan et al., (c) van de Vijver et al., (d) Miller
et al., (e) Sotirious et al., (f) Bild et al., (g) Oh et al., (h) Sorlie et al., (i) Takahashi et al., (j) Ma et al., (k) Minn et al. Kaplan-Meier analysis was
used to evaluate the significance of outcome difference between the two groups. P values were calculated by the log-rank test.
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the 286 training samples into high-risk and low-risk groups with signif-
icantly different outcome (P < .00001; Figure 2b). Importantly, by
performing 1000 Monte Carlo simulations, we found that the proba-
bility for a randomly selected subset of 73 genes to cluster the same
samples with equivalent or better significance was less than .001, re-
affirming that the performance of our 73-gene signature could not
be achieved by chance.
To validate the prediction power of our 73-gene signature, we col-
lected all public breast carcinoma data sets (n = 11) with available
patient survival information from the ONCOMINE [16] database.
The 73-gene signature was then applied to predict individual samples
within each data set into either high-risk or low-risk group using the
nearest centroid classification. Strikingly, in 10 of these 11 data sets,
KM survival analysis revealed a remarkable outcome difference be-
tween the predicted high-risk and low-risk groups (Figure 3, a–j).
For the only data set wherein our outcome signature failed to predict,
it revealed a marginally significant (log-rank P = .15; Figure 3k) as-
sociation with distance metastasis within 5 years. To the best of our
knowledge, this is the first study thus far that reports a breast cancer
outcome predictor that is validated extensively in such many inde-
pendent patient cohorts.
We observed that our gene signature correctly predicted most ER−
breast tumors within individual data sets as high-risk. As a subset of
ER+ tumors relapses regardless of standard antihormone therapy,
they may as well have poor prognosis. It is therefore important to
identify these patients for more effective adjuvant therapies. We thus
Figure 4. The 73-gene outcome signature predicts clinical outcome of ER+ breast cancer. The ER+ breast cancer samples were re-
spectively extracted from the studies of (a) Wang et al., (b) van 't Veer et al., (c) van de Vijver et al., (d) Miller et al., (e) Sotirious et al.,
(f) Bild et al., (g) Oh et al., (h) Sorlie et al., (i) Takahashi et al. The significance of outcome difference between the low-risk and high-risk
groups were estimated by KM survival analysis. P values were calculated by the log-rank test. The data set of Ma et al. is not included in
this analysis as nearly all of its samples are ER+ and thus have been presented in Figure 3j.
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examined the ability of our predictor in stratifying the ER+ tumors
into prognostic subgroups. We have taken the ER+ samples from
each data set and carried out KM survival analysis for the predicted
high-risk and low-risk groups by the 73-gene signature. Notably, KM
survival analysis demonstrated a strong discriminative power of our
73-gene signature in distinguishing ER+ patients with different prog-
noses (Figure 4).
Prognostication of breast cancer outcome may guide the respective
selection of patients at high risk for systemic adjuvant therapy.
However, there is no guarantee that these selected patients will
actually benefit from the therapy. It is therefore of important clin-
ical value to predict therapy responsiveness and to spare some pa-
tients from unnecessary adjuvant therapies that have side effects
and cause more harm than good. For example, endocrine therapy
may be sufficient for some node-positive and ER-positive patients,
and more aggressive adjuvant therapy may not additionally help
these patients. Of the 11 data sets we analyzed above, four contained
patient treatment information. We extracted hormone-treated sam-
ples from each data set and assessed whether our gene predictor
was able to predict patient response to hormonal therapies. Again,
we predicted the hormone-treated samples into high-risk and low-
risk groups. Importantly, in each cohort, we observed significantly
different outcome for the two predicted groups, suggesting an ability
of our signature in therapy prediction (Figures 3j and 5, a–c).
To further confirm the association of our gene signature with es-
trogen sensitivity, we determined whether the 73-gene signature is
able to classify ER+/ER− cell lines in vitro. We performed hierarchi-
cal clustering based on the expression pattern of the 73 genes in
five ER− and three ER+ cell lines. Interestingly, we found that the
73 genes perfectly separated the eight cell lines into their respective
ER+ and ER− clusters (Figure W1 b), demonstrating that our signa-
ture genes are specific to estrogen signaling. Furthermore, as we se-
lected our estrogen-induced genes based on expression induction at
relative early time points (not later than 24 hours) after 17β-estradiol
treatment, we hypothesized that this subset of 73 genes is also en-
riched for direct targets of ER. Concordantly, comparative analysis
with ER-occupied genes described in a previous study [25] identified
a significant overlap (P = .0001), reconfirming the specificity of our
signature to estrogen activity.
As estrogen may also play an important role in the development of
glioma [27] and lung cancer, especially lung adenocarcinoma
[28,29], we examined our outcome signature in three glioma and
one lung adenocarcinoma data sets. Notably, our gene signature suc-
cessfully predicted patient outcome, with P = .0006 for the Freije
et al. glioma [30], P = .008 for the Phillips et al. glioma [31], P = .11
for the Nutt et al. glioma [32], and P = .006 for the Bhattacharjee et al.
lung adenocarcinoma [33] data sets (Figure 5, d–j).
Our Outcome Signature Predicts Patient Survival
Independent of Clinical Criteria and Outperforms
Known Predictors
Global gene expression profiling of breast cancer has yielded a num-
ber of prognostic signatures in the last decade. To properly evaluate the
predictive power of our signature, we compared it with established
clinical parameters as well as previously reported gene predictors. We
first compared our signature with an 822-gene estrogen-regulated sig-
nature (termed as estrogen-SAM ) developed by Oh et al. [18] based
on the Significance Analysis of Microarrays (SAM) that classified the
Figure 5. The 73-gene outcome signature predicts clinical outcome in tamoxifen-treated (a–c) breast cancer subcohorts, (d–f) gliomas,
and (g) lung adenocarcinoma. The low-risk and high-risk groups were predicted by the 73-gene signature with nearest centroid classi-
fication. KM analysis was used to evaluate the significance of outcome difference between the two groups. P values were calculated by
the log-rank test.
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ER+ cases of the Rosetta data set (n = 225) into prognostic subtypes
[8]. We selected the Rosetta data as the test data set because it has been
routinely used as a validation data set for breast cancer outcome signa-
tures. Multivariate Cox proportional-hazards regression analysis of these
patients showed that both our signature and the estrogen-SAM signature
were significant predictors of relapse-free survival (RFS), independent
of standard clinical factors (RFS, P = .002 and P = .004 respectively;
Table 1). Importantly, our outcome signature was by far the strongest pre-
dictor for both relapse-free and OS (RFS, P = .002, Hazard ratio [HR]:
2.24, 95% confidence interval [CI]: 1.35–3.70; and OS, P = .001, HR:
3.27, 95%CI: 1.62–6.62). Thus, our outcome signature achieved better
predictive power whereas using substantially fewer genes. In addition,
our signature comprised solely of estrogen-regulated genes, thus repre-
senting the biologic significance of estrogen activity. By contrast, the
estrogen-SAM signature genes were selected based on their differential ex-
pression between two tumor subtypes predefined by estrogen-regulated
genes, and hence may or may not themselves be regulated by estrogen.
We next extended the comparison of our signature and the estrogen-
SAM signature to the Rosetta 70-gene signature as well using the
Rosetta data set. As the Rosetta signature used a subset of 44 sam-
ples during its development, to avoid potential bias these samples
were excluded from our analysis. Importantly, our signature and
the Rosetta 70-gene signature were both significant predictors of
relapse-free survival (P = .026 and P = .021 respectively; Table 2)
in this data set. Surprisingly, our signature was the only significant
predictor of OS (P = .008), independent of other clinical parameters
and signatures. To further compare the performance of our sig-
nature to previously reported breast cancer gene signatures, we ex-
amined their respective predictive abilities on multiple data sets. As
shown in Table W3, the Rosetta 70-gene signature, Oncotype DX
gene predictor, and our gene signature demonstrated superior per-
formance over other signatures whereas our gene signature showed
overall best performance.
To investigate the molecular difference between our signature and
other breast cancer gene predictors of similar size, we examined the
number of overlapping genes. Interestingly, only two (PRC1 and
CENPA), one (CD44), and three (BRRN1, CDCA8, and MYBL2)
genes overlapped between our 73-gene signature and the Rosetta
70-gene signature [9], the Wang et al. [10] 76-gene signature, and
the Miller et al. [5] 32-gene signature, respectively. This lack of
overlap suggests that our signature is composed of genes distinct from
previously reported gene predictors. Nevertheless, two-way contin-
gency table analysis revealed strong associations between prediction
results of individual samples made by our outcome signature and the
Rosetta 70-gene signature, the wound-response signature and the
intrinsic-subtype model [7] (Table W4). These findings are consis-
tent with previously reported study that distinct gene predictors, al-
though with little overlap in terms of gene identity, may have high
rates of concordance in prediction results for individual samples [34].
Taken together, our distinct gene signature outperformed other
known predictors whereas being concordant in outcome prediction
of individual samples.
Table 1. Multivariate Cox Proportional Hazards Analysis for ER+ Tumors in the Data Set of van de Vijver et al. (n = 225).
Variable Relapse-Free Survival Overall Survival
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
Our estrogen-regulated signature 2.24 (1.35–3.70) .002 3.27 (1.62–6.62) .001
The Oh et al. estrogen-SAM gene signature (IIE vs IE) 2.32 (1.31–4.11) .004 2.24 (0.95–5.28) .066
Age 0.94 (0.89–0.98) .004 0.94 (0.89–1.00) .069
Size (diameter >2 cm vs <2 cm) 1.49 (0.93–2.37) .095 1.41 (0.76–2.61) .280
Tumor grade
(intermediate vs well differentiated) 1.40 (0.72–2.72) .320 2.02 (0.65–6.28) .230
(poorly vs well differentiated) 1.30 (0.64–2.63) .460 2.86 (0.91–9.02) .070
Node status
(1–3 vs 0 positive nodes) 1.82 (0.93–3.57) .082 1.65 (0.66–4.18) .290
(>3 vs 0 positive nodes) 2.87 (1.23–6.74) .015 2.22 (0.69–7.11) .180
Hormonal or chemotherapy vs no adjuvant therapy 0.33 (0.16–0.66) .002 0.43 (0.17–1.13) .086
Table 2. Multivariate Cox Proportional Hazards Analysis for ER+ Tumors in the Data Set of van de Vijver et al. After Excluding Samples Used for the Training Model of van ’t Veer et al. (n = 181).
Variable Relapse-Free Survival Overall Survival
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
Our estrogen-regulated signature 2.01 (1.09–3.72) .026 3.63 (1.40–9.42) .008
70-Gene signature (poor vs good) 2.42 (1.14–5.14) .021 2.37 (0.72–7.85) .160
The Oh et al. estrogen-SAM gene signature (IIE vs IE) 1.83 (0.95–3.52) .070 1.71 (0.62–4.75) .300
Age 0.97 (0.92–1.03) .340 1.00 (0.92–1.07) .900
Size (diameter >2 cm vs <2 cm) 1.18 (0.68–2.04) .560 1.29 (0.60–2.77) .510
Tumor grade
(intermediate vs well differentiated) 0.97 (0.47–2.00) .930 1.33 (0.39–4.49) .650
(poorly vs well differentiated) 0.67 (0.29–1.54) .350 1.63 (0.46–5.75) .450
Node status
(1–3 vs 0 positive nodes) 1.86 (0.90–3.88) .096 1.76 (0.63–4.92) .280
(>3 vs 0 positive nodes) 3.56 (1.39–9.14) .008 2.84 (0.77–10.5) .120
Hormonal or chemotherapy vs no adjuvant therapy 0.33 (0.16–0.68) .003 0.38 (0.14–1.03) .056
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Discussion
There is established precedence for clinical use of molecular markers
to help decide customized therapy for individuals with breast can-
cer. For example, ER and PR, and ERBB2 have been used to assess
potential response to hormonal therapy and trastuzumab (Herceptin),
respectively. Molecular signatures have been developed from micro-
array profiling of cancer to provide prognostication of recurrence or
distant metastases, thus serving as the basis for selecting high-risk pa-
tients for adjuvant therapy. However, it remains challenging to deter-
mine which patients should be selected for adjuvant systemic therapy.
A single marker such as ER has been found insufficient to fully stratify
patient into different diagnostic/prognostic subtypes. In this study, we
aimed to identify a transcriptional fingerprint of estrogen, which re-
flects the downstream activity of estrogen signaling pathway, and thus
may be a more efficient predictor of breast cancer recurrence.
Unlike most previously reported breast cancer signatures that were
developed using supervised analysis based on patient diagnosis/
prognosis status [5–10], our signature was discovered by specifically
selecting estrogen-regulated genes, thus representing the activities of
estrogen signaling, a key biologic characteristic of breast cancer tu-
mors. We profiled gene expression of three breast cancer cell lines
during early time-points after estrogen treatment. We observed that
more than 80% of our estrogen-regulated genes were already activated
within 1 to 2 hours after estrogen treatment in the MCF-7 breast
cancer cell line. Genome-wide location analysis confirmed that a sig-
nificant portion of these genes are directly occupied by ER, suggesting
an enrichment of direct ER target genes in our signature. In addition,
our gene signature distinguishes ER+ and ER− patients, as well as sep-
arates patients who did well with hormonal therapy from those who
did not, indicating its specificity in monitoring estrogen activity.
In developing the 73-gene outcome signature we focused on
in vitro estrogen-regulated genes and further selected a subset that is as-
sociated with patient outcome in vivo in human breast tumors. These
genes are unique as they are both related to estrogen signaling pathway
and are associated with patient survival; that is, they represent a subset
of downstream targets of estrogen signaling that are predictive of breast
cancer outcome. Concordantly, comparative analyses with previously
reported breast cancer predictors revealed rare overlap in gene identity,
yet high concordance in outcome prediction of individual samples.
Therefore, our gene signature reflects estrogen activity and is distinct
from previously reported gene signatures that mainly capture expres-
sional differences between cancer prognostic subtypes.
Our 73-gene signature predicts breast cancer outcome in 10 of
11 data sets we analyzed. Besides correctly assigning most ER− tumors
in each data set into high-risk group, this signature is able to stratify
the ER+ samples into prognostic subtypes, suggesting that it may bet-
ter reflect tumor aggressiveness than ER status alone. Most impor-
tantly, our signature provides additional prognostic information
beyond standard clinical factors and yields overall best performance
against previously reported breast cancer outcome predictors.
Further validation and refinement of our signature using additional
data sets with larger cohorts of breast cancer patients will help strengthen
its clinical value. This study lays the ground for future characteriza-
tion of individual signature genes to facilitate in the understanding of
breast cancer progression as well as help select genes with critical roles
in estrogen response for breast cancer therapy. Furthermore, as reverse
transcription–polymerase chain reaction assays of paraffin-embedded
tissues have recently been developed [6], it is technically feasible to de-
velop an reverse transcription–polymerase chain reaction assay of our
73-gene signature for future validation and, potentially later on, for
clinical usage. Our signature may be useful in the selection of high-
risk patients for adjuvant therapy as well as in sparing some hormone-
sensitive patients from aggressive therapy.
References
[1] Clemons M and Goss P (2001). Estrogen and the risk of breast cancer. N Engl
J Med 344, 276–285.
[2] Jordan VC (2003). Tamoxifen: a most unlikely pioneering medicine. Nat Rev
Drug Discov 2, 205–213.
[3] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005). Effects of
chemotherapy and hormonal therapy for early breast cancer on recurrence and
15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717.
[4] Brenner H (2002). Long-term survival rates of cancer patients achieved by the
end of the 20th century: a period analysis. Lancet 360, 1131–1135.
[5] Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P,
Klaar S, Liu ET, et al. (2005). An expression signature for p53 status in human
breast cancer predicts mutation status, transcriptional effects, and patient sur-
vival. Proc Natl Acad Sci USA 102, 13550–13555.
[6] Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG,
Watson D, Park T, et al. (2004). A multigene assay to predict recurrence of
tamoxifen-treated, node-negative breast cancer. N Engl J Med 351, 2817–2826.
[7] Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, Akslen LA, et al. (2000). Molecular portraits of human
breast tumours. Nature 406, 747–752.
[8] van de Vijver MJ, He YD, van ’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber
GJ, Peterse JL, Roberts C, MartonMJ, et al. (2002). A gene-expression signature as a
predictor of survival in breast cancer. N Engl J Med 347, 1999–2009.
[9] van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL,
van der Kooy K, Marton MJ, Witteveen AT, et al. (2002). Gene expression pro-
filing predicts clinical outcome of breast cancer. Nature 415, 530–536.
[10] Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D,
Timmermans M, Meijer-van Gelder ME, Yu J, et al. (2005). Gene-expression
profiles to predict distant metastasis of lymph-node–negative primary breast
cancer. Lancet 365, 671–679.
[11] Pujol P, Daures JP, Thezenas S, Guilleux F, Rouanet P, and Grenier J (1998).
Changing estrogen and progesterone receptor patterns in breast carcinoma
during the menstrual cycle and menopause. Cancer 83, 698–705.
[12] Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, and Lippman ME
(2005). GREB 1 is a critical regulator of hormone dependent breast cancer
growth. Breast Cancer Res Treat 92, 141–149.
[13] Creighton CJ, Cordero KE, Larios JM, Miller RS, Johnson MD, Chinnaiyan
AM, Lippman ME, and Rae JM (2006). Genes regulated by estrogen in breast
tumor cells in vitro are similarly regulated in vivo in tumor xenografts and
human breast tumors. Genome Biol 7, R28.
[14] Bolstad BM, Irizarry RA, Astrand M, and Speed TP (2003). A comparison of
normalization methods for high density oligonucleotide array data based on var-
iance and bias. Bioinformatics 19, 185–193.
[15] Leek JT, Monsen E, Dabney AR, and Storey JD (2006). EDGE: extraction and
analysis of differential gene expression. Bioinformatics 22, 507–508.
[16] Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette
T, Pandey A, and Chinnaiyan AM (2004). ONCOMINE: a cancer microarray
database and integrated data-mining platform. Neoplasia 6, 1–6.
[17] Bair E and Tibshirani R (2004). Semi-supervised methods to predict patient
survival from gene expression data. PLoS Biol 2, E108.
[18] Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, and Perou
CM (2006). Estrogen-regulated genes predict survival in hormone receptor–
positive breast cancers. J Clin Oncol 24, 1656–1664.
[19] Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, and Katzenellenbogen BS
(2003). Profiling of estrogen up- and down-regulated gene expression in human
breast cancer cells: insights into gene networks and pathways underlying estro-
genic control of proliferation and cell phenotype. Endocrinology 144, 4562–4574.
[20] Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-
Sundaram S, Wei JT, Rubin MA, Pienta KJ, et al. (2007). Integrative molecular
concept modeling of prostate cancer progression. Nat Genet 39, 41–51.
[21] Buterin T, Koch C, and Naegeli H (2006). Convergent transcriptional profiles
induced by endogenous estrogen and distinct xenoestrogens in breast cancer
cells. Carcinogenesis 27, 1567–1578.
Neoplasia Vol. 10, No. 1, 2008 Estrogen-Regulated Genes Predicts Breast Cancer Outcome Yu et al. 87
[22] Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, and Katzenellenbogen BS
(2004). Selective estrogen receptor modulators: discrimination of agonistic
versus antagonistic activities by gene expression profiling in breast cancer cells.
Cancer Res 64, 1522–1533.
[23] Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR, and Katzenellenbogen BS
(2004). Transcriptional profiling of estrogen-regulated gene expression via estro-
gen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and
common target genes for these receptors. Endocrinology 145, 3473–3486.
[24] Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P,
Praz V, Haibe-Kains B, et al. (2006). Gene expression profiling in breast cancer:
understanding the molecular basis of histologic grade to improve prognosis.
J Natl Cancer Inst 98, 262–272.
[25] Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS,
Keeton EK, Fertuck KC, Hall GF, et al. (2006). Genome-wide analysis of es-
trogen receptor binding sites. Nat Genet 38, 1289–1297.
[26] Lin CY, Strom A, Vega VB, Kong SL, Yeo AL, Thomsen JS, Chan WC, Doray B,
Bangarusamy DK, Ramasamy A, et al. (2004). Discovery of estrogen receptor alpha
target genes and response elements in breast tumor cells. Genome Biol 5, R66.
[27] Sribnick EA, Ray SK, and Banik NL (2006). Estrogen prevents glutamate-
induced apoptosis in C6 glioma cells by a receptor-mediated mechanism.
Neuroscience 137, 197–209.
[28] Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, and Pietras RJ
(2007). Estrogen receptor signaling pathways in human non–small cell lung
cancer. Steroids 72, 135–143.
[29] Stabile LP and Siegfried JM (2004). Estrogen receptor pathways in lung cancer.
Curr Oncol Rep 6, 259–267.
[30] Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM,
Mischel PS, and Nelson SF (2004). Gene expression profiling of gliomas
strongly predicts survival. Cancer Res 64, 6503–6510.
[31] Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A,
Nigro JM, Colman H, Soroceanu L, et al. (2006). Molecular subclasses of high-
grade glioma predict prognosis, delineate a pattern of disease progression, and
resemble stages in neurogenesis. Cancer Cell 9, 157–173.
[32] Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U,
Hartmann C, McLaughlin ME, Batchelor TT, et al. (2003). Gene expression–
based classification of malignant gliomas correlates better with survival than his-
tological classification. Cancer Res 63, 1602–1607.
[33] Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C,
Beheshti J, Bueno R, Gillette M, et al. (2001). Classification of human lung
carcinomas by mRNA expression profiling reveals distinct adenocarcinoma sub-
classes. Proc Natl Acad Sci USA 98, 13790–13795.
[34] Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van ’t Veer LJ, and
Perou CM (2006). Concordance among gene-expression–based predictors for
breast cancer. N Engl J Med 355, 560–569.
[35] Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L,
Huang F, Klaar S, et al. (2005). Gene expression profiling spares early breast can-
cer patients from adjuvant therapy: derived and validated in two population-based
cohorts. Breast Cancer Res 7, R953–R964.
88 Estrogen-Regulated Genes Predicts Breast Cancer Outcome Yu et al. Neoplasia Vol. 10, No. 1, 2008
Figure W1. Estrogen-regulated genes on in vivo human breast carcinomas and in vitro breast cancer cell lines. (a) K-mean clustering
representation of the 532 estrogen-regulated probe sets in the training cohort of 286 primary breast carcinomas (left) and the
corresponding survival curves (right). The low-risk and high-risk groups were derived from k-mean clustering (k = 2) and determined
by Kaplan-Meier (KM) survival analysis. (b) Hierarchical clustering of three ER+ and four ER− cell lines in the space of 73 genes from our
outcome signature. All cells are supplemented with 10% FBS.
Table W1. Molecular Concept Map Analysis of the 532 Estrogen-Regulated Gene Set.
MCM Group Type MCM ID No. MCM Concept Name P Odds Ratio
GO biologic process 101773 Mitosis 1.60e−11 8.7
102303 Protein folding 2.00e−07 4
101476 DNA replication 1.20e−06 5.3
102831 Purine nucleotide biosynthesis 2.40e−05 23.61
102027 Regulation of cell cycle 4.50e−05 3.04
102757 Cell cycle 5.30e−05 3.35
101778 tRNA processing 6.30e−05 8.73
101579 Cytokinesis 6.50e−05 4.09
103038 rRNA processing 1.10e−04 7.9
102314 Protein biosynthesis 1.40e−04 2.62
101484 DNA replication initiation 3.40e−04 10.73
101852 DNA repair .002 2.98
104378 Antigen processing, through MHC class II .002 9.42
102045 G2/M transition of mitotic cell cycle .002 17.63
102415 Protein–nucleus import .003 8.56
Literature-defined concepts 7217562 Estrogen-regulated in breast cancer cell 2.40e−08 15.59
119273 Upregulated by estradiol in breast cancer cells 1.40e−07 21.83
122632 Upregulated after a 6-hour estrogen treatment 6.00e−05 7.27
117954 Upregulated by estradiol in osteosarcoma cells .001 4.35
ONCOMINE gene expression signatures 122413 Over-expressed in ER+ (Zhao) 9.30e−07 4.79
121567 Over-expressed in ER+ (van de Vijver) 5.40e−06 4.31
122823 Over-expressed in PR+ (Zhao) 2.00e−05 2.17
22585576 Over-expressed in ER+ cell lines (Neve) 6.40e−05 2
8619592 Over-expressed in ER+ (Sotiriou) 8.20e−05 3.52
22209686 Over-expressed in ER+ (Hess) 2.60e−10 2.79
22208976 Over-expressed in ER+ (Miller) 2.50e−09 5.48
122510 Over-expressed in ER+ (Wang) 1.40e−08 2.56
22211376 Over-expressed in ER+ (Yu) 2.40e−07 5.63
22210226 Over-expressed in high grade 3 (Miller) 9.30e−49 5.07
22209756 Over-expressed in high grade 3 (Bittner) 6.20e−43 5.89
8467132 Over-expressed in high grade 3 (Sotiriou) 6.50e−41 6.27
22210346 Over-expressed in high grade 3 (Hess) 7.60e−38 4.34
131034 Over-expressed in high grade 3 (van de Vijver) 2.10e−30 4.96
22239956 Over-expressed in high grade 3 (Ma) 1.30e−19 9.69
125550 Over-expressed in high grade 3 (Zhao) 8.10e−19 3.03
120566 Over-expressed in high grade 3 (Sorlie) 8.00e−11 3.78
135628 Over-expressed in relapse (Wang) 7.20e−10 2.73
8467192 Over-expressed in dead (Pawitan) 3.70e−32 3.78
131411 Over-expressed in relapse (van de Vijver) 2.20e−30 3.76
123530 Over-expressed in metastasis (van de Vijver) 1.50e−23 4.22
138906 Over-expressed in basal-like subtype (Farmer) 2.70e−21 3.13
Table W2. The 73 Genes in the Outcome Signature.
Affymetrix U133A Probe Set Gene Symbol
202148_s_at PYCR1
203564_at FANCG
209773_s_at RRM2
202954_at UBE2C
202095_s_at BIRC5
202870_s_at CDC20
221436_s_at CDCA3
214096_s_at SHMT2
218336_at PFDN2
221520_s_at CDCA8
214095_at SHMT2
203145_at SPAG5
204092_s_at AURKA
218726_at DKFZp762E1312
211881_x_at IGL@
206472_s_at TLE3
202107_s_at MCM2
216913_s_at KIAA0690
219215_s_at SLC39A4
201710_at MYBL2
201584_s_at DDX39
204252_at CDK2
219910_at HYPE
201421_s_at WDR77
213906_at MYBL1
211576_s_at COL18A1
218984_at PUS7
205284_at KIAA0133
220177_s_at TMPRSS3
204489_s_at CD44
204490_s_at CD44
209835_x_at CD44
205322_s_at MTF1
218481_at EXOSC5
220029_at ELOVL2
208305_at PGR
209273_s_at HBLD2
220038_at SGK3
204498_s_at ADCY9
208922_s_at STX5
218620_s_at HEMK1
208688_x_at EIF3S9
212022_s_at MKI67
206364_at KIF14
218663_at HCAP-G
206976_s_at HSPH1
218270_at MRPL24
218009_s_at PRC1
209408_at KIF2C
204817_at ESPL1
38158_at ESPL1
204962_s_at CENPA
203755_at BUB1B
222039_at LOC146909
204441_s_at POLA2
212949_at BRRN1
219502_at NEIL3
210466_s_at SERBP1
204633_s_at RPS6KA5
203710_at ITPR1
215193_x_at HLA-DRB1
212473_s_at MICAL2
213933_at PTGER3
202464_s_at PFKFB3
220266_s_at KLF4
212848_s_at C9orf3
202417_at KEAP1
204792_s_at IFT140
200706_s_at LITAF
215273_s_at TADA3L
221261_x_at MAGED4
214736_s_at ADD1
220935_s_at CDK5RAP2
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Table W4. Two-way Contingency Table Analysis Measuring the Association between Our Signa-
ture, 70-Gene Signature, Wound-Response Signature, and the Estrogen-SAM Signature in the
Data Set of van de Vijver et al.
(A) Two-way Contingency Table in the Data Set of van de Vijver et al. (n = 295)
Our Estrogen-Regulated Signature 70-Gene Signature (No. of Patients)
Good Poor
Low-risk 106 53
High-risk 9 127
Statistics for two-way table analysis
P <.0001
Cramer’s V 0.617
(B) Two-way Contingency Table in the Data Set of van de Vijver et al. (n = 295)
Our Estrogen-Regulated Signature
Wound-Response Signature (No. of Patients)
Activated Quiescent
Low-risk 98 61
High-risk 130 6
Statistics for two-way table analysis
P <.0001
Cramer’s V 0.404
(C) Two-way Contingency Table in the Data Set of van de Vijver et al. (n = 295)
Intrinsic Subtype
Our Estrogen-Regulated Signature (No. of Patients)
Low-Risk High-Risk
Basal-like 3 50
Luminal A 108 15
Luminal B 13 42
HER2+ and ER− 9 26
Normal-like 26 3
Statistics for two-way table analysis
P <.0001
Cramer’s V 0.720
(D) Two-way Contingency Table on ER+ Tumors in the Data Set of van de Vijver et al. (n = 225)
Our Estrogen-Regulated Signature
Estrogen-SAM Signature (No. of Patients)
Group IE Group IIE
Low-risk 90 58
High-risk 12 65
Statistics for two-way table analysis
P <.0001
Cramer’s V 0.431
